In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
Professor Warren Clements, interventional radiologist and head of the UAE service at The Alfred, said despite the proven safety and efficacy of the procedure – which was developed in the 1990s – it is simply not provided as an option to many women, something he urgently wants to change.
“Fibroids are highly prevalent in society and women need access to a range of different treatments so that they can choose what is the best for them,” Prof Clements said in an interview with Australian Health Journal.
“Every year, many women have a hysterectomy who would be suitable for a non-surgical alternative. UAE is an amazing non-surgical treatment and allows women to keep their uterus if they want to.”
The procedure is all done through a single pinhole incision, whereas a hysterectomy requires open surgery. It involves using low-dose x-rays and contrast dye to guide catheters through the arteries towards fibroids in the uterus. A medication is used to block the blood supply to the fibroids, which causes them to shrink. The procedure takes about half an hour, is done under ‘twilight’ sedation, and only requires one overnight recovery stay.
”Many women aren’t aware that this is a very minor procedure compared to hysterectomy,” Prof Clements said. “Women can resume normal activities the following day. The recovery is short, and most women can go back to work within a week. More than 90 per cent of women with heavy periods will have significant improvement in their symptoms after UAE.”
Professor Warren Clements, is also Honorary Researcher – Interventional Radiology, National Trauma Research Institute, Professor, Interventional Radiologist (IR) and the Head of Fluoroscopy in the Department of Radiology at Alfred Health. He is also a Fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR).
Credit: Alfred Health
You Might also like
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Surgical Site Infection (SSI) Synopsis, including modifiable and non-modifiable risk factors
Talking to the Australian Health Journal, Professor Russo states there is a particular concern in joint operations, such as hip or knee replacements, as infections in these areas can have severe consequences, including the removal of the infected joint, prolonged treatment, and significant costs for both hospitals and patients. Despite the substantial impact of surgical site infections, Australia lacks a national surveillance program for these infections, making it challenging to obtain accurate data. However, an estimate suggests that around 45,000 surgical site infections occur annually in Australia, resulting in approximately 900 deaths.
-
Spinal implant technology eyes global opportunity
Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.